CUE241220C4000
- 0.00
- 0.000.00%
Cue Biopharma Newsroom
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $2
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
Stifel Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $4
Stifel Nicolaus Remains a Buy on Cue Biopharma (CUE)
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $2
A Quick Look at Today's Ratings for Cue Biopharma(CUE.US), With a Forecast Between $2 to $6
Cue Biopharma Analyst Ratings
Stifel Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $3
Analysts Have Conflicting Sentiments on These Healthcare Companies: Perrigo Company (PRGO), Cue Biopharma (CUE) and United Therapeutics (UTHR)
Stifel Nicolaus Sticks to Their Buy Rating for Cue Biopharma (CUE)
JMP Securities Maintains Market Outperform on Cue Biopharma, Lowers Price Target to $2
Cue Biopharma Analyst Ratings
Piper Sandler Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $3
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Cuts Target Price to $2
Cue Biopharma Receives 'Buy' Rating Amid Strategic Shift and Promising Autoimmune Therapeutics Pipeline
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Cue Biopharma Analyst Ratings